- Home
- SYTA vs RNTX Comparison
SYTA vs RNTX Comparison
Compare SYTA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYTA
- RNTX
- Stock Information
- Founded
- SYTA N/A
- RNTX 2001
- Country
- SYTA Canada
- RNTX United States
- Employees
- SYTA N/A
- RNTX N/A
- Industry
- SYTA Telecommunications Equipment
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- SYTA Telecommunications
- RNTX Health Care
- Exchange
- SYTA Nasdaq
- RNTX Nasdaq
- Market Cap
- SYTA 38.2M
- RNTX 40.3M
- IPO Year
- SYTA 2020
- RNTX N/A
- Fundamental
- Price
- SYTA $3.73
- RNTX $1.11
- Analyst Decision
- SYTA
- RNTX
- Analyst Count
- SYTA 0
- RNTX 0
- Target Price
- SYTA N/A
- RNTX N/A
- AVG Volume (30 Days)
- SYTA 2.1M
- RNTX 46.6K
- Earning Date
- SYTA 08-15-2025
- RNTX 08-13-2025
- Dividend Yield
- SYTA N/A
- RNTX N/A
- EPS Growth
- SYTA N/A
- RNTX N/A
- EPS
- SYTA N/A
- RNTX N/A
- Revenue
- SYTA $11,740,024.00
- RNTX N/A
- Revenue This Year
- SYTA $18.41
- RNTX N/A
- Revenue Next Year
- SYTA N/A
- RNTX N/A
- P/E Ratio
- SYTA N/A
- RNTX N/A
- Revenue Growth
- SYTA 33.58
- RNTX N/A
- 52 Week Low
- SYTA $0.93
- RNTX $1.05
- 52 Week High
- SYTA $53.64
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- SYTA 52.02
- RNTX N/A
- Support Level
- SYTA $3.20
- RNTX N/A
- Resistance Level
- SYTA $3.45
- RNTX N/A
- Average True Range (ATR)
- SYTA 0.41
- RNTX 0.00
- MACD
- SYTA -0.12
- RNTX 0.00
- Stochastic Oscillator
- SYTA 34.12
- RNTX 0.00
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.